Business
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021
AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call. Conference dial-in:877-402-3914International dial-in:631-865-5294Conference ID:6206747Conference Call Name:Plus Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call Following the live call, a replay will be available on the Company’s website under the 'Investor Relations' section. The webcast will be available on the Company’s website for 90 days following the live call. About Plus Therapeutics, Inc. Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-loo...